Detailed data from the Phase 1 first-in-human study of BRB-002 will be presented at the American College of Cardiology Scientific Session in March 2025. A Phase 2 proof-of-concept trial of BRB-002 in ...

It has been suggested that novel treatment options are needed that target both aspects of the disease. Evidence from basic and clinical studies suggests that testosterone has an immunomodulatory ...

IO Biotech, a clinical-stage biopharmaceutical company with a global footprint, is developing novel, immune-modulating cancer ... responses to a single epitope treatment. The ability to repress ...

Adimune Inc., a subsidiary of Aditxt Inc., has successfully completed preclinical studies for its antigen-specific gene therapy, ADI-100. BioWorld Science Dermatologic Endocrine/metabolic Immune ...

Aditxt, Inc.’s subsidiary, Adimune, Inc., has completed preclinical studies for its ADI-100 immune modulation therapy, positioning it for human trials targeting Type 1 Diabetes, Psoriasis ...

The US Food and Drug Administration has granted orphan drug designation (ODD) to Tempest Therapeutics' oral, selective ...

Former US President Jimmy Carter passed away at age 100 after a prolonged battle with cancer and 22 months in hospice care.

These patterns suggested distinct immune modulation roles within the plaque ... cancer patients undergoing immune checkpoint inhibitor treatment and offered a foundation for designing safer ...

( MENAFN - EIN Presswire) market-grow.png" width="300" height="166" alt="Chronic Hepatitis B market Growth" /> David Correa Allied Market Research +1 800-792-5285 email us here Visit us on social ...

Adenosine deaminase 2 (ADA2) has been identified as a regulator of toll-like receptor 9 (TLR9) activation in response to nucleic acids, according to a recent study.